|
|
Article: New Peanut Allergy Drug Shows Great Promise; Corporate Squabble Halts Clinical Trials.
- Article from:
- PR Newswire
- Article date:
- March 12, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
FAIRFAX, Va. -- FAIRFAX, Va., March 12 /PRNewswire/ -- This week scientists announced in the New England Journal of Medicine the promising results of clinical trials of TNX-901, a drug that helps block the allergic response to peanut allergy. Word of this major advance initially elated the 1.5 million Americans with peanut allergy, but the elation was short-lived as word spread that the clinical trials in seven research centers across the country may be halted July 1st due to a legal squabble involving Genentech, Novartis, and Tanox over development rights. The suspension of the clinical trials left patients and physicians alike stunned and angry.
"This drug ...